Oxford Nanopore Technologies PLC
Company Profile
Business description
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
Contact
Edmund Halley Road
Gosling Building, Oxford Science Park
OxfordOxfordshireOX4 4DQ
GBRT: +44 8450347900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,281
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
stocks
The fight for Insignia continues
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,927.62 | 35.01 | 0.44% |
| DAX 40 | 21,394.93 | 16.60 | -0.08% |
| Dow JONES (US) | 44,523.34 | 41.73 | -0.09% |
| FTSE 100 | 8,502.35 | 62.85 | -0.73% |
| HKSE | 20,066.19 | 365.63 | 1.86% |
| NASDAQ | 20,017.35 | 36.33 | -0.18% |
| Nikkei 225 | 39,931.98 | 26.89 | -0.07% |
| NZX 50 Index | 13,024.70 | 35.38 | -0.27% |
| S&P 500 | 6,114.98 | 3.73 | -0.06% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,252.63 | 22.46 | 0.70% |